Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Nuvectis Pharma, Inc.NASDAQ: NVCT
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.26, compared with -$0.27 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.31.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$1.05 (+20.8%) for the fiscal year ending Dec 2026, a step up from the -18.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.26+16.1% QoQ
- Last fiscal yearDec 2025
- -$1.32-18.9% YoY
- LTMMar 2026
- -$1.31-18.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.7% | +12.7% | +9.0 pp |
| 1 year | -18.9% | +20.8% | +39.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.32) USD
- Year-over-year change
- -18.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.32) | -18.9% |
| FY2024 | 2024-12-31 | (1.11) | +22.4% |
| FY2023 | 2023-12-31 | (1.43) | +5.3% |
| FY2022 | 2022-12-31 | (1.51) | -38.5% |
| FY2021 | 2021-12-31 | (1.09) | — |
EPS (Diluted) vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 EPS (Diluted) of -$1.31 is the 7th highest of the 11 companies compared; the peer median is -$1.13.
- Its year-over-year change of -18.0% is the 8th highest of 11, against a peer median of +23.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.22 | +99.9% | — | |
| LTM Mar 2026 | -$0.43 | -5.9% | — | |
| LTM Jun 2026 | -$0.44 | +30.8% | — | |
| LTM Mar 2026 | -$0.92 | -29.6% | — | |
| LTM Mar 2026 | -$1.1 | -23.6% | — | |
| LTM Mar 2026 | -$1.17 | +40.3% | — | |
| LTM Mar 2026 | -$1.31 | -18.0% | — | |
| LTM Mar 2026 | -$1.44 | +23.0% | — | |
| LTM Mar 2026 | -$1.84 | -35.3% | — | |
| LTM Mar 2026 | -$2.73 | +23.5% | — | |
| LTM Mar 2026 | -$2.8 | +27.6% | — | |
| Peer median (excluding NVCT) | -$1.13 | +23.3% | — | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| Weighted Avg Shares | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
| Weighted Avg Shares (Diluted) | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.